Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

Finasteride may help prevent prostate cancer.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.

This study found that both oral minoxidil and finasteride altered prostate tissue in mice, with more severe changes seen in finasteride-treated groups, suggesting greater implications for male reproductive health compared to minoxidil.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

In this case study, a male miniature dachshund with alopecia was diagnosed with estrogen-secreting Sertoli cell tumors and seminoma, with the alopecia resolving post-surgical removal of the tumor.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This study found that follicular stem cells in hair follicles are more sensitive to the antiproliferative effects of glucocorticoids compared to basal keratinocytes due to incomplete desensitization.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

This study found that combining D-004 with finasteride results in more significant prevention of testosterone-induced prostate enlargement in rats compared to using either treatment alone.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This study described the clinical characteristics of keratosis pilaris atrophicans faciei in 14 patients, noting that earlier diagnosis may enable more targeted treatment options.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This study investigated a patient with spinal and bulbar muscular atrophy who had 68 CAG repeats, revealing early onset and unique symptoms not previously documented in the condition.